Jazz Pharmaceuticals plc - Asset Resilience Ratio

Latest as of March 2026: 8.68%

Jazz Pharmaceuticals plc (J7Z) has an Asset Resilience Ratio of 8.68% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check J7Z PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

€1.03 Billion

≈ $1.20 Billion USD Cash + Short-term Investments

Total Assets

€11.86 Billion

≈ $13.87 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Jazz Pharmaceuticals plc's Asset Resilience Ratio has changed over time. See how leveraged is Jazz Pharmaceuticals plc's balance sheet to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Jazz Pharmaceuticals plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see J7Z market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€1.03 Billion	8.68%
Total Liquid Assets	€1.03 Billion	8.68%

Asset Resilience Insights

Limited Liquidity: Jazz Pharmaceuticals plc maintains only 8.68% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Jazz Pharmaceuticals plc Industry Peers by Asset Resilience Ratio

Compare Jazz Pharmaceuticals plc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Argen-X F:1AE	Biotechnology	10.93%
CSL Ltd AU:CSL	Biotechnology	0.41%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	57.90%
HLB Co. Ltd KQ:028300	Biotechnology	0.72%
SOLENO THERAPEUT. DL-001 F:6XC	Biotechnology	41.74%
MBX Biosciences, Inc. Common Stock NASDAQ:MBX	Biotechnology	87.20%
Tourmaline Bio Inc. NASDAQ:TRML	Biotechnology	77.17%
PharmaResources (Shanghai) Co. Ltd. A SHE:301230	Biotechnology	16.35%

Annual Asset Resilience Ratio for Jazz Pharmaceuticals plc (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Jazz Pharmaceuticals plc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	9.01%	€1.05 Billion ≈ $1.23 Billion	€11.66 Billion ≈ $13.63 Billion	+4.18pp
2024-12-31	4.83%	€580.00 Million ≈ $678.08 Million	€12.01 Billion ≈ $14.04 Billion	+3.78pp
2023-12-31	1.05%	€120.00 Million ≈ $140.29 Million	€11.39 Billion ≈ $13.32 Billion	--
2022-12-31	0.00%	€0.00 ≈ $0.00	€10.84 Billion ≈ $12.67 Billion	--
2021-12-31	0.00%	€0.00 ≈ $0.00	€12.30 Billion ≈ $14.38 Billion	--
2020-12-31	16.45%	€1.07 Billion ≈ $1.26 Billion	€6.54 Billion ≈ $7.64 Billion	+8.50pp
2019-12-31	7.94%	€440.00 Million ≈ $514.41 Million	€5.54 Billion ≈ $6.48 Billion	-1.95pp
2018-12-31	9.90%	€515.00 Million ≈ $602.09 Million	€5.20 Billion ≈ $6.08 Billion	+5.70pp
2017-12-31	4.20%	€215.00 Million ≈ $251.36 Million	€5.12 Billion ≈ $5.99 Billion	+2.95pp
2016-12-31	1.25%	€60.00 Million ≈ $70.15 Million	€4.80 Billion ≈ $5.61 Billion	--

pp = percentage points

About Jazz Pharmaceuticals plc

F:J7Z Germany Biotechnology

Market Cap

$14.31 Billion

€12.24 Billion EUR

Market Cap Rank

#2005 Global

#413 in Germany

Share Price

€195.15

Change (1 day)

-1.54%

52-Week Range

€90.06 - €207.10

All Time High

€207.10